Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3282541 | Clinical Gastroenterology and Hepatology | 2014 | 11 Pages |
Abstract
There were no significant differences in the percentage of patients with moderate-to-severe active Crohn's disease who achieved clinical responses (Response-70) or clinical remission after 4 weeks' administration of tofacitinib (1, 5, or 15 mg) or placebo twice daily. However, a large percentage of patients given placebo achieved Response-70 or remission. Reductions in C-reactive protein and fecal calprotectin levels among patients given the 15-mg dose of tofacitinib indicate its biologic activity. ClinicalTrials.gov number: NCT00615199.
Keywords
TNFIBDQHDLCDAITofacitinibANCSAEJanus kinasehigh-density lipoproteinrandomized control trialCrohn’s diseaseAbsolute neutrophil countCrohn’s Disease Activity Indexadverse eventSerious adverse eventconfidence intervaltumor necrosis factorLow-density lipoproteinLDLInflammatory Bowel Disease QuestionnaireC-reactive proteinCRPJAK
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
William J. Sandborn, Subrata Ghosh, Julian Panes, Ivana Vranic, Wenjin Wang, Wojciech Niezychowski,